Back to News
Market Impact: 0.45
FDA Grants Full Approval To Lilly's Inluriyo Plus Verzenio For ESR1-Mutated Breast Cancer
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Eli Lilly received full FDA approval for Inluriyo (imlunestrant), an oral estrogen-receptor antagonist, in combination with Verzenio (abemaciclib), a CDK4/6 inhibitor. The approval expands Lilly's oncology treatment portfolio and supports commercialization of the combination regimen.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
LLY0.82
More News
- JPMorgan initiates TRex Bio stock coverage with overweight rating
- Santoli: AI bull market almost surely needs tech stocks to recover to keep advancing
- AI stocks fall as Texas governor result raises data center risks
- Trump promised every adult $5,000 if Republicans kept control of Congress. Thanks to Democrats, taxpayers won’t have to pay up and blow up the debt
- ‘Lawyer up’: Democrats take the House, and warn Trump’s family businesses are first in line for subpoenas
- Democratic Party flips US Senate in 2026 midterm elections